Search results (1320)
« Back to PublicationsPolo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Syed N. et al, (2011), Cancer Res, 71, 3317 - 3327
The biological and therapeutic relevance of mRNA translation in cancer.
Blagden SP. and Willis AE., (2011), Nat Rev Clin Oncol, 8, 280 - 291
Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
Gillies RS. et al, (2011), BRITISH JOURNAL OF SURGERY, 98, 3 - 3
Shared care protocol for the management of essential thrombocythaemia patients in primary care
Sweeney C. et al, (2011), BRITISH JOURNAL OF HAEMATOLOGY, 153, 55 - 55
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
Khan OA. et al, (2011), Br J Cancer, 104, 750 - 755
Circulating melanoma cells and survival in metastatic melanoma.
Rao C. et al, (2011), Int J Oncol, 38, 755 - 760
Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
Gillies RS. et al, (2011), Eur Radiol, 21, 274 - 280
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.
Goardon N. et al, (2011), Cancer Cell, 19, 138 - 152
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
Khan OA. et al, (2011), British Journal of Cancer
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Leijen S. et al, (2011), Cancer Chemotherapy and Pharmacology, 1 - 10
CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
Ait-Tahar K. et al, (2011), Haematologica, 96, 78 - 86
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
Khan OA. et al, (2011), Br J Cancer, 104, 1822 - 1827
Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
Cooper CDO. et al, (2011), PLoS One, 6
Molecular targets in ovarian cancer
Agarwal R. and Blagden S., (2011), Cancer and Chemotherapy Reviews, 6, 37 - 44
Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian Cancer
Gungor H. et al, (2011), EUROPEAN JOURNAL OF CANCER, 47, 12 - 13
Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.
Gungor H. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma
Gillies RS. et al, (2011), British Journal of Surgery
Angiogenesis - still a worthwhile target for breast cancer therapy?
Lord S. and Harris AL., (2010), Breast Cancer Res, 12 Suppl 4
Co Existence of LMPP Like and GMP Like Leukemia Stem Cells In Acute Myeloid Leukemia
Goardon N. et al, (2010), BLOOD, 116, 46 - 46